Lithuania Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

Published:  Aug 2022 Report Code: KSI061613355 Pages: 75

The Lithuania flu diagnostic and treatment market is projected to grow at a CAGR of 4.70% throughout the forecast period to reach US$29.801 million in 2027, from US$21.603 million in 2020.

The market in Lithuania is anticipated to grow at a notable CAGR, primarily due to the availability of modern healthcare in the country. Healthcare in the country is majorly funded by the government through the national health insurance scheme. This, in turn, is leading to the adoption of costly treatments and medical services, which are anticipated to propel the flu diagnostic and treatment market in Lithuania. Under the national health insurance scheme, all employers are bound to register their employees this scheme, which covers the entire health of the employees and their family members also. Similarly, the high incidence of intense flu throughout the country is also expected to significantly drive the demand for diagnostics and treatment services, which is also propelling the market growth during the next five years.

The Lithuanian flu diagnostic and treatment market is expected to grow due to the high intensity of flu, the adoption of tests & treatments, and others.

The high intensity of the seasonal flu throughout the country is also considered one of the key factors anticipated to propel the demand for flu diagnostics and treatments, which, in turn, will drive the market growth significantly throughout the forecast period and beyond. Furthermore, there was a high number of deaths observed throughout the flu season during the year 2019, which amplified the adoption of treatments and tests in the country as a proactive measure to mitigate the number of deaths, which is also one of the prime factors for the flu diagnostics and treatment market growth in the country. In addition, the seasonal flu outbreak in the country is expected to drive the flu diagnostic and treatment market throughout the forecast period and beyond.

In October 2021, the WHO elaborated on how it had to convince the Lithuanian healthcare workers to take the influenza vaccine, before starting an influenza drive for pregnant women in Lithuania. The vaccination drive started with a series of lectures that were open to doctors, nurses, and midwives. WHO gave strong support to executing this series and provided Lithuanians with influenza vaccines for pregnant women. Such initiatives by international organizations are expected to drive the market.

Product Offering

  • In February 2021, Thermo Fisher Scientific offered two multiplex tests that allow the user to detect and differentiate multiple respiratory viruses at the same time. A single test for COVID-19, Flu A, Flu B, and RSV Combo kit can accurately identify and distinguish between SARS-CoV-2, Influenza, and other respiratory syncytial viruses (RSV). This test is marketed and made available in countries like Austria, Bahrain, Belgium, Chile, Lithuania, Denmark, Hungry, etc.
  • F. Hoffmann-La Roche Ltd. provides the Cobas® SARS-CoV- 2 and Influenza A & B tests. The company claims that the test kit can differentiate between COVID-19 and Flu. The test only takes 20 mins with minimum cross-contamination and risk of exposure during testing with the closed-system design.

COVID-19 Impact

Since the healthcare sector was overburdened with COVID-19 patients, the diagnostics and therapeutics for influenza cases declined to affect the market potential in 2020. During the pandemic, a rapid decrease in influenza cases was observed all over the country. Influenza seasonal vaccine drives were reduced due to the spread of COVID-19. Social distancing measures have played role in reducing influenza virus transmission. WHO reported, that globally influenza activity continued to decrease after a peak in march 2022. But, the changes in the behaviour post-pandemic have resulted in increased influenza activity in Lithuania. The ECDC (European Centre for Disease Prevention and Control has also stated that in the 2021/2022 flu season the cases of influenza are higher than in the previous year. As of the tenth week of 2022, Lithuania has reported 1,290,295 cases of influenza. Hence, the Lithuanian diagnostics and treatment market is expected to grow in the forecast period.

Segmentation

  • By Type of Flu
    • Type A
    • Type B
  • By Offering
    • Diagnostics
      • Rapid Influenza Diagnostic Test
      • Rapid Molecular Assay
      • Others
    • Therapeutics
  • By Age Group
    • 0-14 Years
    • 15-64 Years
    • >=65 Years
  • By End-User
    • Hospital Laboratory
    • Outpatient Clinic
    • Reference Laboratory
1. Introduction
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Lithuania Flu Diagnostic and Treatment Market Analysis, By Type of Flu
5.1. Introduction
5.2. Type A
5.3. Type B

6. Lithuania Flu Diagnostic and Treatment Market Analysis, By Offering
6.1. Introduction
6.2. Diagnostics
6.2.1. Rapid Influenza Diagnostic Test
6.2.2. Rapid Molecular Assay
6.2.3. Others
6.3. Therapeutics

7. Lithuania Flu Diagnostic and Treatment Market Analysis, By Age Group
7.1. Introduction
7.2. 0-14 Years
7.3. 15-64 Years
7.4. >=65 Years

8. Lithuania Flu Diagnostic and Treatment Market Analysis, By End-User 
8.1. Introduction
8.2. Hospital Laboratory
8.3. Outpatient Clinic
8.4. Reference Laboratory

9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix

10. Company Profiles
10.1. F. Hoffmann-La Roche Ltd
10.2. Thermo Fisher Scientific Inc.
10.3. 3M
10.4. Meridian Bioscience
10.5. QIAGEN 
10.6. FUJIFILM Europe GmbH

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific Inc.

3M

Meridian Bioscience

QIAGEN

FUJIFILM Europe GmbH

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us